Works matching DE "PROTEIN-tyrosine kinase inhibitors"
Results: 5000
Lung Cancer in 'Never-Smokers': A Unique Entity.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 1, p. 29
- By:
- Publication type:
- Article
Chronic Phase Chronic Myeloid Leukemia: More Drugs, More Lives Saved, New Challenges.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
The Unfolding Story of Imatinib Mesylate for Chronic Myeloid Leukemia.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
Optimal First-Line Treatment of Chronic Myeloid Leukemia: How to Use Imatinib and What Role for Newer Drugs?
- Published in:
- Oncology (08909091), 2007, v. 21, n. 6, p. 653
- By:
- Publication type:
- Article
New Therapeutics for Soft-Tissue Sarcomas in Adults.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 1, p. 123
- By:
- Publication type:
- Article
Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, and Head and Neck Cancers.
- Published in:
- Oncology (08909091), 2006, v. 20, p. 15
- By:
- Publication type:
- Article
EGFR Inhibitors in Lung Cancer.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 13, p. 1707
- By:
- Publication type:
- Article
Current Strategies in the Management of Lung Cancer.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 13, p. 1667
- By:
- Publication type:
- Article
PHASE 3 TRIAL TO EXPLORE RCC COMBINATION.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 34
- By:
- Publication type:
- Article
Combination of belzutifan plus cabozantinib is active in advanced RCC: Treatment shrank tumors in 88% of patients and led to a disease control rate of 90%.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 34
- By:
- Publication type:
- Article
FDA approves combination nivolumab/cabozantinib in RCC.
- Published in:
- Urology Times, 2021, v. 49, n. 2, p. 7
- By:
- Publication type:
- Article
Nivolumab/cabozantinib combo impresses as frontline RCC treatment: Combination reduces risk of disease progression or death by 49% versus sunitinib.
- Published in:
- Urology Times, 2020, v. 48, n. 11, p. 32
- By:
- Publication type:
- Article
Cabozantinib combo induces clinical activity in advanced ccRCC.
- Published in:
- Urology Times, 2020, v. 48, n. 10, p. 41
- By:
- Publication type:
- Article
Cabozantinib shows intriguing activity in heavily pretreated urothelial carcinoma.
- Published in:
- Urology Times, 2020, v. 48, n. 9, p. 22
- By:
- Publication type:
- Article
New Products & Services.
- Published in:
- 2019
- Publication type:
- Product Review
First-line therapy for advanced RCC remains controversial amid new approvals: Combination treatment of choice for intermediate-, poor-risk disease not clear, according to expert.
- Published in:
- Urology Times, 2019, v. 47, n. 6, p. 8
- By:
- Publication type:
- Article
Accelerated approval granted for metastatic urothelial Ca agent.
- Published in:
- Urology Times, 2019, v. 47, n. 5, p. 32
- Publication type:
- Article
Pembro plus axitinib is new standard in advanced RCC.
- Published in:
- Urology Times, 2019, v. 47, n. 5, p. 4
- By:
- Publication type:
- Article
Guest Editorial. A landslide trial for patients with metastatic RCC.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
Advanced RCC combo Tx significantly improves OS.
- Published in:
- Urology Times, 2019, v. 47, n. 4, p. 36
- Publication type:
- Article
RCC immunotherapy combo extends survival.
- Published in:
- Urology Times, 2018, v. 46, n. 3, p. 6
- By:
- Publication type:
- Article
Oral agent improves survival in advanced RCC patients.
- Published in:
- Urology Times, 2016, v. 44, n. 9, p. 10
- By:
- Publication type:
- Article
Breakthrough therapy designation granted for advanced RCC agent.
- Published in:
- Urology Times, 2015, v. 43, n. 10, p. 33
- Publication type:
- Article
Soy derivative may lower PSA in PCa patients.
- Published in:
- Urology Times, 2003, v. 31, n. 12, p. 17
- By:
- Publication type:
- Article
Current and emerging immunobiologic therapies for atopic dermatitis.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 226, doi. 10.1007/s40267-024-01075-8
- By:
- Publication type:
- Article
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 2, p. 45, doi. 10.1007/s40267-023-01041-w
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 357, doi. 10.1007/s40267-023-01025-w
- By:
- Publication type:
- Article
Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Imatinib-induced pleural effusion: A case report.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Pregnancy outcomes post‐kidney transplantation across 23 years.
- Published in:
- Australian & New Zealand Journal of Obstetrics & Gynaecology, 2024, v. 64, n. 3, p. 269, doi. 10.1111/ajo.13786
- By:
- Publication type:
- Article
European consensus document on mast cell tumours in dogs and cats.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. e1, doi. 10.1111/j.1476-5829.2012.00341.x
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor special issue Tyrosine kinase inhibitor special issue.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 161, doi. 10.1111/j.1476-5829.2012.00339.x
- By:
- Publication type:
- Article
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 163, doi. 10.1111/j.1476-5829.2012.00342.x
- By:
- Publication type:
- Article
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines*.
- Published in:
- Veterinary & Comparative Oncology, 2012, v. 10, n. 3, p. 223, doi. 10.1111/j.1476-5829.2012.00335.x
- By:
- Publication type:
- Article
Abstracts presented at the 30th Annual VCS Conference, San Diego, CA, USA, 29 October-1 November 2010.
- Published in:
- 2011
- Publication type:
- Abstract
Cover Feature: Optimization of the Lead Compound NVP‐BHG712 as a Colorectal Cancer Inhibitor (Chem. Eur. J. 23/2023).
- Published in:
- Chemistry - A European Journal, 2023, v. 29, n. 23, p. 1, doi. 10.1002/chem.202300918
- By:
- Publication type:
- Article
Activation of RhoA and FAK induces ERK-mediated osteopontin expression in mechanical force-subjected periodontal ligament fibroblasts.
- Published in:
- Molecular & Cellular Biochemistry, 2010, v. 335, n. 1/2, p. 263, doi. 10.1007/s11010-009-0276-1
- By:
- Publication type:
- Article
Genistein abolishes nucleoside uptake by cardiac fibroblasts.
- Published in:
- Molecular & Cellular Biochemistry, 2009, v. 332, n. 1/2, p. 121, doi. 10.1007/s11010-009-0181-7
- By:
- Publication type:
- Article
The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas.
- Published in:
- Molecular & Cellular Biochemistry, 2007, v. 295, n. 1, p. 19, doi. 10.1007/s11010-006-9267-7
- By:
- Publication type:
- Article
Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.
- Published in:
- Journal of Interventional Cardiac Electrophysiology, 2024, v. 67, n. 1, p. 111, doi. 10.1007/s10840-023-01575-z
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor–associated ventricular arrhythmias: a case series and review of literature.
- Published in:
- Journal of Interventional Cardiac Electrophysiology, 2023, v. 66, n. 5, p. 1165, doi. 10.1007/s10840-022-01400-z
- By:
- Publication type:
- Article
Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
- Published in:
- Journal of Computer-Aided Molecular Design, 2022, v. 36, n. 1, p. 25, doi. 10.1007/s10822-021-00432-3
- By:
- Publication type:
- Article
Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).
- Published in:
- Journal of Computer-Aided Molecular Design, 2015, v. 29, n. 7, p. 619, doi. 10.1007/s10822-015-9841-8
- By:
- Publication type:
- Article
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs.
- Published in:
- Cancer & Metastasis Reviews, 2024, v. 43, n. 4, p. 1561, doi. 10.1007/s10555-024-10188-5
- By:
- Publication type:
- Article
The role of histone H3 lysine demethylases in glioblastoma.
- Published in:
- Cancer & Metastasis Reviews, 2023, v. 42, n. 2, p. 445, doi. 10.1007/s10555-023-10114-1
- By:
- Publication type:
- Article
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.
- Published in:
- Cancer & Metastasis Reviews, 2022, v. 41, n. 1, p. 193, doi. 10.1007/s10555-022-10021-x
- By:
- Publication type:
- Article
Gastrointestinal stromal tumor: a review of current and emerging therapies.
- Published in:
- Cancer & Metastasis Reviews, 2021, v. 40, n. 2, p. 625, doi. 10.1007/s10555-021-09961-7
- By:
- Publication type:
- Article
Imatinib Mesylate Does Not Increase Bone Volume In Vivo.
- Published in:
- Calcified Tissue International, 2011, v. 88, n. 1, p. 16, doi. 10.1007/s00223-010-9429-1
- By:
- Publication type:
- Article
Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study.
- Published in:
- World Journal of Urology, 2025, v. 43, n. 1, p. 1, doi. 10.1007/s00345-025-05443-5
- By:
- Publication type:
- Article
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.
- Published in:
- World Journal of Urology, 2024, v. 42, n. 1, p. 1, doi. 10.1007/s00345-024-05252-2
- By:
- Publication type:
- Article